Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacteriophage Vb_Sm_GA
- Development stage
- Preclinical
- Lead developer
- David Tvildiani Medical University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
Bacteriophage Vb_Sm_GA is a novel lytic bacteriophage isolated from wastewater in Tbilisi, Georgia, by researchers at the Eliava Institute of Bacteriophages, Microbiology and Virology [1]. It specifically targets *Stenotrophomonas maltophilia*, an emerging Gram-negative multidrug-resistant (MDR) nosocomial pathogen [1]. In vitro studies have demonstrated that Vb_Sm_GA has strong lytic activity against certain MDR and biofilm-producing *S. maltophilia* clinical isolates, maintaining low bacterial concentrations in time-kill assays [1]. It is being investigated for its therapeutic potential against antibiotic-resistant *S. maltophilia* infections [1].
- Other names
- phage Vb_Sm_GA
Beyond the preview
Go deeper on bacteriophage Vb_Sm_GA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacteriophage Vb_Sm_GA.